Rules, roles, and room for discussion in gadoxetic acid-enhanced magnetic resonance liver imaging: Current knowledge and future Challenges

Magnetic Resonance in Medical Sciences

Volumn 12, Issue 3, 2013, Pages 161-175

  Utaroh, Motosugi ^a   Ichikawa, Tomoaki ^a   Araki, Tsutomu ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Gadoxetic acid; Liver; Magnetic resonance imaging

Indexed keywords

CONTRAST MEDIUM; DIAGNOSTIC AGENT; GADOLINIUM PENTETATE; GADOXETIC ACID;

ALGORITHM; DIFFERENTIAL DIAGNOSIS; HUMAN; IMAGE ENHANCEMENT; LIVER; LIVER TUMOR; METHODOLOGY; NEOVASCULARIZATION (PATHOLOGY); NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; REVIEW;

ALGORITHMS; CONTRAST MEDIA; DIAGNOSIS, DIFFERENTIAL; GADOLINIUM DTPA; HUMANS; IMAGE ENHANCEMENT; LIVER; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84884864210     PISSN: 13473182     EISSN: 18802206     Source Type: Journal    
DOI: 10.2463/mrms.2012-0085     Document Type: Review

References (99)

1. Frydrychowicz A, Lubner MG, Brown JJ, et al. Hepatobiliary MR imaging with gadolinium-based contrast agents. J Magn Reson Imaging 2012; 35: 492-511.
2. Doo KW, Lee CH, Choi JW, Lee J, Kim KA, Park CM. "Pseudo washout" sign in high-flow hepatic hemangioma on gadoxetic acid contrast-enhanced MRI mimicking hypervascular tumor. AJR Am J Roentgenol 2009; 193:W490-W496.
3. Motosugi U, Ichikawa T, Onohara K, et al. Distinguishing hepatic metastasis from hemangioma using gadoxetic acid-enhanced magnetic resonance imaging. Invest Radiol 2011; 46:359-365.
4. Motosugi U, Ichikawa T, Sou H, et al. Liver parenchymal enhancement of hepatocyte-phase images in Gd-EOB-DTPA-enhanced MR imaging: which biological markers of the liver function affect the enhancement? J Magn Reson Imaging 2009; 30:1042-1046.
5. Kuwatsuru R, Brasch RC, Muähler A, et al. Definition of liver tumors in the presence of diffuse liver disease: comparison of findings at MR imaging with positive and negative contrast agents. Radiology 1997; 202:131-138.
6. Tamada T, Ito K, Higaki A, et al. Gd-EOBDTPA- enhanced MR imaging: evaluation of hepatic enhancement effects in normal and cirrhotic livers. Eur J Radiol 2011; 80:e311-e316.
7. Higaki A, Tamada T, Sone T, et al. Potential clinical factors affecting hepatobiliary enhancement at Gd-EOB-DTPA-enhancedMRimaging. Magn Reson Imaging 2012; 30:689-693.
8. Motosugi U, Ichikawa T, Muhi A, et al. Magnetic resonance elastography as a predictor of insuf- ficient liver enhancement on gadoxetic acid-enhanced hepatocyte-phasemagnetic resonance imaging in patients with type C hepatitis and Child- Pugh class A disease. Invest Radiol 2012; 47:566-570.
9. Tamada T, Ito K, Sone T, et al. Dynamic contrastenhanced magnetic resonance imaging of abdominal solid organ and major vessel: comparison of enhancement effect between Gd-EOB-DTPA and Gd-DTPA. J Magn Reson Imaging 2009; 29:636-640.
10. Kuähn JP, Hegenscheid K, Siegmund W, Froehlich CP, Hosten N, Puls R. Normal dynamic MRI enhancement patterns of the upper abdominal organs: gadoxetic acid compared with gadobutrol. AJR Am J Roentgenol 2009; 193:1318-1323.
11. Zech CJ, Vos B, Nordell A, et al. Vascular enhancement in early dynamic liver MR imaging in an animal model: comparison of two injection regimen and two different doses Gd-EOB-DTPA (gadoxetic acid) with standard Gd-DTPA. Invest Radiol 2009; 44:305-310.
12. Hamm B, Staks T, Muähler A, et al. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 1995; 195:785-792.
13. Tanimoto A, Lee JM, Murakami T, Huppertz A, Kudo M, Grazioli L. Consensus report of the 2nd International Forum for Liver MRI. Eur Radiol 2009; 19 Suppl 5:S975-S989.
14. Tanimoto A, Higuchi N, Ueno A. Reduction of ringing artifacts in the arterial phase of gadoxetic acid-enhanced dynamic MR imaging. Magn Reson Med Sci 2012; 11:91-97.
15. Lufkin RB, Pusey E, Stark DD, Brown R, Leikind B, Hanafee WN. Boundary artifact due to truncation errors in MR imaging. AJR Am J Roentgenol 1986; 147:1283-1287.
16. Oshio K, Feinberg DA. GRASE (Gradient- and spin-echo) imaging: a novel fast MRI technique. Magn Reson Med 1991; 20:344-349.
17. Haradome H, Grazioli L, Tsunoo M, et al. Can MR fluoroscopic triggering technique and slow rate injection provide appropriate arterial phase images with reducing artifacts on gadoxetic acid-DTPA (Gd-EOB-DTPA)-enhanced hepatic MR imaging? J Magn Reson Imaging 2010; 32:334-340.
18. Motosugi U, Ichikawa T, Sou H, et al. Dilution method of gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI). J Magn Reson Imaging 2009; 30:849-854.
19. Tamada T, Ito K, Yoshida K, et al. Comparison of three different injection methods for arterial phase of Gd-EOB-DTPA enhanced MR imaging of the liver. Eur J Radiol 2011; 80:e284-e288.
20. Golfieri R, Renzulli M, Lucidi V, Corcioni B, Trevisani F, Bolondi L. Contribution of the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI to dynamic MRI in the detection of hypovascular small (Ã2 cm) HCC in cirrhosis. Eur Radiol 2011; 21:1233-1242.
21. Onishi H, Kim T, Imai Y, et al. Hypervascular hepatocellular carcinomas: detection with gadoxetate disodium-enhanced MR imaging and multiphasic multidetector CT. Eur Radiol 2012; 22: 845-854.
22. Motosugi U, Ichikawa T, Sano K, et al. Doubledose gadoxetic acid-enhanced magnetic resonance imaging in patients with chronic liver disease. Invest Radiol 2011; 46:141-145.
23. Reimer P, Rummeny EJ, Shamsi K, et al. Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence. Radiology 1996; 199: 177-183.
24. Huppertz A, Haraida S, Kraus A, et al. Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT-initial observations. Radiology 2005; 234:468-478.
25. Yamamoto A, Tamada T, Sone T, Higashi H, Yamashita T, Ito K. Gd-EOB-DTPA-enhanced magnetic resonance imaging findings of nondiffuse fatty change of the liver. J Comput Assist Tomogr 2010; 34:868-873.
26. Tamada T, Ito K, Sone T, Kanki A, Sato T, Higashi H. Gd-EOB-DTPA enhanced MR imaging: evaluation of biliary and renal excretion in normal and cirrhotic livers. Eur J Radiol 2011; 80: e207-e211.
27. Motosugi U, Ichikawa T, Tominaga L, et al. Delay before the hepatocyte phase of Gd-EOB-DTPAenhanced MR imaging: is it possible to shorten the examination time? Eur Radiol 2009; 19:2623-2629.
28. Jeong HT, Kim MJ, Park MS, et al. Detection of liver metastases using gadoxetic-enhanced dynamic and 10- and 20-minute delayed phase MR imaging. J Magn Reson Imaging 2012; 35:635-643.
29. Sofue K, Tsurusaki M, Tokue H, Arai Y, Sugimura K. Gd-EOB-DTPA-enhanced 3.0T MR imaging: quantitative and qualitative comparison of hepatocyte-phase images obtained 10 min and 20 min after injection for the detection of liver metastases from colorectal carcinoma. Eur Radiol 2011; 21:2336-2343.
30. Bashir MR, Merkle EM. Improved liver lesion conspicuity by increasing the flip angle during hepatocyte phase MR imaging. Eur Radiol 2011; 21:291-294.
31. Bashir MR, Husarik DB, Ziemlewicz TJ, Gupta RT, Boll DT, Merkle EM. Liver MRI in the hepatocyte phase with gadolinium-EOB-DTPA: does increasing the flip angle improve conspicuity and detection rate of hypointense lesions? J Magn Reson Imaging 2012; 35:611-616.
32. Haradome H, Grazioli L, Al manea K, et al. Gadoxetic acid disodium-enhanced hepatocyte phase MRI: can increasing the flip angle improve focal liver lesion detection? JMagn Reson Imaging 2012; 35:132-139.
33. Nagle SK, Busse RF, Brau AC, et al. High resolution navigated three-dimensional T(1)-weighted hepatobiliary MRI using gadoxetic acid optimized for 1.5 Tesla. J Magn Reson Imaging 2012; 36: 890-899.
34. Frydrychowicz A, Nagle SK, D'Souza SL, Vigen KK, Reeder SB. Optimized high-resolution contrast- enhanced hepatobiliary imaging at 3 tesla: a cross-over comparison of gadobenate dimeglumine and gadoxetic acid. J Magn Reson Imaging 2011; 34:585-594.
35. Saito K, Araki Y, Park J, et al. Effect of Gd-EOBDTPA on T2-weighted and diffusion-weighted images for the diagnosis of hepatocellular carcinoma. J Magn Reson Imaging 2010; 32:229-234.
36. Tamada T, Ito K, Yoshida K, et al. T2-weighted magnetic resonance imaging of the liver: evaluation of the effect in signal intensity after Gd-EOBDTPA enhancement. J Comput Assist Tomogr 2010; 34:182-186.
37. Kim YK, Kwak HS, Kim CS, Han YM. Detection and characterization of focal hepatic tumors: a comparison of T2-weighted MR images before and after the administration of gadoxectic acid. J Magn Reson Imaging 2009; 30:437-443.
38. Choi JS, Kim MJ, Choi JY, Park MS, Lim JS, Kim KW. Diffusion-weighted MR imaging of liver on 3.0-Tesla system: effect of intravenous administration of gadoxetic acid disodium. Eur Radiol 2010; 20:1052-1060.
39. Muhi A, Ichikawa T, Motosugi U, Sou H, Sano K, Araki T. Diffusion- and T2-weighted MR imaging of the liver: effect of intravenous administration of gadoxetic acid disodium. Magn Reson Med Sci 2012; 11:185-191.
40. Ringe KI, Gupta RT, Brady CM, et al. Respiratory- triggered three-dimensional T2-weighted MR cholangiography after injection of gadoxetate disodium: is it still reliable? Radiology 2010; 255:451-458.
41. Nakamura Y, Ohmoto T, Saito T, Kajima T, Nishimaru E, Ito K. Effects of gadolinium-ethoxybenzyl- diethylenetriamine pentaacetic acid on T2- weighted MRCP. Magn Reson Med Sci 2009; 8: 143-148.
42. Kim KA, Kim MJ, Park MS, et al. Optimal T2- weighted MR cholangiopancreatographic images can be obtained after administration of gadoxetic acid. Radiology 2010; 256:475-484.
43. Ringe KI, Husarik DB, Gupta RT, Boll DT, Merkle EM. Hepatobiliary transit times of gadoxetate disodium (Primovist®) for protocol optimization of comprehensive MR imaging of the biliary system-what is normal? Eur J Radiol 2011; 79:201-205.
44. Shimofusa R, Ueda T, Kishimoto T, et al. Magnetic resonance imaging of hepatocellular carcinoma: a pictorial review of novel insights into pathophysiological features revealed by magnetic resonance imaging. J Hepatobiliary Pancreat Sci 2010; 17: 583-589.
45. Floriani I, Torri V, Rulli E, et al. Performance of imaging modalities in diagnosis of liver metastases from colorectal cancer: a systematic review and meta-analysis. J Magn Reson Imaging 2010; 31: 19-31.
46. Niekel MC, Bipat S, Stoker J. Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a metaanalysis of prospective studies including patients who have not previously undergone treatment. Radiology 2010; 257:674-684.
47. Huppertz A, Balzer T, Blakeborough A, et al. Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings. Radiology 2004; 230:266-275.
48. Muhi A, Ichikawa T, Motosugi U, et al. Diagnosis of colorectal hepatic metastases: comparison of contrast-enhanced CT, contrast-enhanced US, superparamagnetic iron oxide-enhanced MRI, and gadoxetic acid-enhanced MRI. J Magn Reson Imaging 2011; 34:326-335.
49. Kim YK, Lee YH, Kwak HS, Kim CS, Han YM. Detection of liver metastases: gadoxetic acid-enhanced three-dimensional MR imaging versus ferucarbotran-enhanced MR imaging. Eur J Radiol 2010; 73:131-136.
50. Kim YK, Lee MW, Lee WJ, et al. Diagnostic accuracy and sensitivity of diffusion-weighted and of gadoxetic acid-enhanced 3-T MR imaging alone or in combination in the detection of small liver metastasis (≤ 1.5 cm in diameter). Invest Radiol 2012; 47:159-166.
51. Kanematsu M, Goshima S, Watanabe H, et al. Diffusion/perfusion MR imaging of the liver: practice, challenges, and future. Magn Reson Med Sci 2012; 11:151-161.
52. Motosugi U, Ichikawa T, Morisaka H, et al. Detection of pancreatic carcinoma and liver metastases with gadoxetic acid-enhanced MR imaging: comparison with contrast-enhanced multi-detector row CT. Radiology 2011; 260:446-453.
53. Park HS, Lee JM, Choi HK, Hong SH, Han JK, Choi BI. Preoperative evaluation of pancreatic cancer: comparison of gadolinium-enhanced dynamic MRI with MR cholangiopancreatography versus MDCT. J Magn Reson Imaging 2009; 30: 586-595.
54. Mitchell DG, Saini S, Weinreb J, et al. Hepatic metastases and cavernous hemangiomas: distinction with standard- and triple-dose gadoteridol-enhanced MR imaging. Radiology 1994; 193:49-57.
55. Soyer P, Dufresne AC, Somveille E, Scherrer A. Hepatic cavernous hemangioma: appearance on T2 -weighted fast spin-echo MR imaging with and without fat suppression. AJR Am J Roentgenol 1997; 168:461-465.
56. Imai Y, Murakami T, Hori M, et al. Hypervascular hepatocellular carcinoma: combined dynamic MDCT and SPIO-enhanced MRI versus combined CTHA and CTAP. Hepatol Res 2008; 38:147-158.
57. Vogl TJ, Kuämmel S, Hammerstingl R, et al. Liver tumors: comparison of MR imaging with Gd-EOBDTPA and Gd-DTPA. Radiology 1996; 200:59-67.
58. Takara K, Saito K, Kusama H, et al. Gd-EOBDTPA- enhanced MR imaging findings of hepatocellular adenoma: correlation with pathological findings. Magn Reson Med Sci 2011; 10:245-249.
59. Zech CJ, Grazioli L, Breuer J, Reiser MF, Schoenberg SO. Diagnostic performance and description of morphological features of focal nodular hyperplasia in Gd-EOB-DTPA-enhanced liver magnetic resonance imaging: results of a multicenter trial. Invest Radiol 2008; 43:504-511.
60. Mohajer K, Frydrychowicz A, Robbins JB, LoeOEer AG, Reed TD, Reeder SB. Characterization of hepatic adenoma and focal nodular hyperplasia with gadoxetic acid. J Magn Reson Imaging 2012; 36:686-696.
61. Grazioli L, Bondioni MP, Haradome H, et al. Hepatocellular adenoma and focal nodular hyperplasia: value of gadoxetic acid-enhanced MR imaging in differential diagnosis. Radiology 2012; 262: 520-529.
62. Karam AR, Shankar S, Surapaneni P, Kim YH, Hussain S. Focal nodular hyperplasia: central scar enhancement pattern using gadoxetate disodium. J Magn Reson Imaging 2010; 32:341-344.
63. Katabathina VS, Menias CO, Shanbhogue AK, Jagirdar J, Paspulati RM, Prasad SR. Genetics and imaging of hepatocellular adenomas: 2011 update. Radiographics 2011; 31:1529-1543.
64. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53:1020-1022.
65. Study Group of Evidence-based Practice Guideline for Liver Cancer. Evidence-based Liver Cancer Practice Guideline. Tokyo: KANEHARA & CO., LTD., 2009.
66. Di Martino M, Marin D, Guerrisi A, et al. Intraindividual comparison of gadoxetate disodium-enhanced MR imaging and 64-section multidetector CT in the detection of hepatocellular carcinoma in patients with cirrhosis. Radiology 2010; 256:806-816.
67. Murakami T, Okada M, Hyodo T. CT versus MR imaging of hepatocellular carcinoma: toward improved treatment decisions. Magn Reson Med Sci 2012; 11:75-81.
68. Karadeniz-Bilgili MY, Braga L, Birchard KR, et al. Hepatocellular carcinoma missed on gadolinium enhanced MR imaging, discovered in liver explants: retrospective evaluation. JMagn Reson Imaging 2006; 23:210-215.
69. Ahn SS, Kim MJ, Lim JS, Hong HS, Chung YE, Choi JY. Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma. Radiology 2010; 255: 459-466.
70. Frericks BB, Loddenkemper C, Huppertz A, et al. Qualitative and quantitative evaluation of hepatocellular carcinoma and cirrhotic liver enhancement using Gd-EOB-DTPA. AJR Am J Roentgenol 2009; 193:1053-1060.
71. Hwang SH, Yu JS, Kim KW, Kim JH, Chung JJ. Small hypervascular enhancing lesions on arterial phase images of multiphase dynamic computed tomography in cirrhotic liver: fate and implications. J Comput Assist Tomogr 2008; 32:39-45.
72. Sun HY, Lee JM, Shin CI, et al. Gadoxetic acidenhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or =2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging. Invest Radiol 2010; 45:96-103.
73. Motosugi U, Ichikawa T, Sou H, et al. Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging. Radiology 2010; 256:151-158.
74. Kudo M. Multistep human hepatocarcinogenesis: correlation of imaging with pathology. J Gastroenterol 2009; 44 Suppl 19:112-118.
75. Matsui O. Imaging of multistep human hepatocarcinogenesis by CT during intra-arterial contrast injection. Intervirology 2004; 47:271-276.
76. Efremidis SC, Hytiroglou P. The multistep process of hepatocarcinogenesis in cirrhosis with imaging correlation. Eur Radiol 2002; 12:753-764.
77. International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the International Consensus Group for Hepatocellular Neoplasia. Hepatology 2009; 49:658-664.
78. Sakamoto M, Hirohashi S, Shimosato Y. Early stages of multistep hepatocarcinogenesis: adenomatous hyperplasia and early hepatocellular carcinoma. Hum Pathol 1991; 22:172-178.
79. Takayasu K, Muramatsu Y, Furukawa H, et al. Early hepatocellular carcinoma: appearance at CT during arterial portography and CT arteriography with pathologic correlation. Radiology 1995; 194: 101-105.
80. Kogita S, Imai Y, Okada M, et al. Gd-EOBDTPA- enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading and portal blood flow. Eur Radiol 2010; 20:2405-2413.
81. Sano K, Ichikawa T, Motosugi U, et al. Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid-enhanced MR imaging. Radiology 2011; 261:834-844.
82. Golfieri R, Grazioli L, Orlando E, et al. Which is the best MRI marker of malignancy for atypical cirrhotic nodules: hypointensity in hepatobiliary phase alone or combined with other features? Classification after Gd-EOB-DTPA administration. J Magn Reson Imaging 2012; 36:647-658.
83. Kitao A, Matsui O, Yoneda N, et al. The uptake transporter OATP8 expression decreases during multistep hepatocarcinogenesis: correlation with gadoxetic acid enhanced MR imaging. Eur Radiol 2011; 21:2056-2066.
84. Matsui O. Multistep hepatocarcinogenesis and early hepatocellular carcinoma: imaging-pathological correlation. In: Arii S, Matsui O, eds. Early diagnosis of hepatocellular carcinoma: imaging and molecular marker. Tokyo: Arc Medium, 2012; 15-34.
85. Bartolozzi C, Battaglia V, Bargellini I, et al. Contrast- enhanced magnetic resonance imaging of 102 nodules in cirrhosis: correlation with histological findings on explanted livers. Abdom Imaging 2013; 38:290-296.
86. Van Beers BE, Pastor CM, Hussain HK. Primovist, Eovist: what to expect? J Hepatol 2012; 57:421-429.
87. Motosugi U, Ichikawa T, Sano K, et al. Outcome of hypovascular hepatic nodules revealing no gadoxetic acid uptake in patients with chronic liver disease. J Magn Reson Imaging 2011; 34:88-94.
88. Kumada T, Toyoda H, Tada T, et al. Evolution of hypointense hepatocellular nodules observed only in the hepatobiliary phase of gadoxetate disodiumenhanced MRI. AJR Am J Roentgenol 2011; 197: 58-63.
89. Saito K, Kotake F, Ito N, et al. Gd-EOB-DTPA enhanced MRI for hepatocellular carcinoma: quantitative evaluation of tumor enhancement in hepatobiliary phase. Magn Reson Med Sci 2005; 4: 1-9.
90. Kitao A, Zen Y, Matsui O, et al. Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR imaging-correlation with molecular transporters and histopathologic features. Radiology 2010; 256:817-826.
91. Tsuboyama T, Onishi H, Kim T, et al. Hepatocellular carcinoma: hepatocyte-selective enhancement at gadoxetic acid-enhanced MR imaging-correlation with expression of sinusoidal and canalicular transporters and bile accumulation. Radiology 2010; 255:824-833.
92. Chen N, Motosugi U, Sano K, et al. Early hepatocellular carcinomas showing isointensity or hyperintensity in gadoxetic acid-enhanced, hepatocyte- phase magnetic resonance images. J Comput Assist Tomogr 2013 (in press).
93. Kobayashi S, Matsui O, Gabata T, et al. Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging findings of borderline lesions at high risk for progression to hypervascular classic hepatocellular carcinoma. J Comput Assist Tomogr 2011; 35:181-186.
94. Moriyama Y, Saito S, Kobayashi S, et al. Evaluation of concanavalin A-induced acute liver injury in rats using an empirical mathematical model and dynamic contrast-enhanced MR imaging with Gd- EOB-DTPA. Magn Reson Med Sci 2012; 11:53-60.
95. Watanabe H, Kanematsu M, Goshima S, et al. Staging hepatic fibrosis: comparison of gadoxetate disodium-enhanced and diffusion-weighted MR imaging-preliminaryobservations. Radiology2011; 259:142-150.
96. Kanki A, Tamada T, Higaki A, et al. Hepatic parenchymal enhancement at Gd-EOB-DTPA-enhanced MR imaging: correlation with morphological grading of severity in cirrhosis and chronic hepatitis. Magn Reson Imaging 2012; 30:356-360.
97. Chen BB, Hsu CY, Yu CW, et al. Clinical and histologic implications of delayed hepatobiliary enhancement on magnetic resonance imaging with gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid. Invest Radiol 2012; 47:649-655.
98. Yamada A, Hara T, Li F, et al. Quantitative evaluation of liver function with use of gadoxetate disodium- enhanced MR imaging. Radiology 2011; 260:727-733.
99. Motosugi U, Ichikawa T, Oguri M, et al. Staging liver fibrosis by using liver-enhancement ratio of gadoxetic acid-enhanced MR imaging: comparison with aspartate aminotransferase-to-platelet ratio index. Magn Reson Imaging 2011; 29:1047-1052.